Risk of diabetic microvascular complications, heart failure, hospitalisation and all-cause mortality with SGLT2i and GLP1-RA in type 2 diabetes: a real-world data study
In this medfyle
Real-world data suggest that SGLT2i and GLP1-RA reduce the risk for macular oedema, heart failure, hospitalisation and all-cause mortality in people with type 2 diabetes over 5 years. SGLT2i reduces the risk for microvascular complications including neuropathy, autonomic neuropathy and retinopathy.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
About this Medfyle
This is a summary of a presentation given at the EASD 2023 Annual Meeting. The content is developed by Infomedica in collaboration with the Diabetes Education Study Group (DESG).
The information and data provided is for information purposes only. The presenting author(s) of the original presentation had no involvement in the creation of this content. The viewpoints expressed may not represent Infomedica, Medfyle, or the DESG.
©2023 Infomedica-Medfyle. All rights reserved.
